222165-70-0

Basic information

• Product Name: 3-tert-Butoxycarbonylamino-propionic acid (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-bis-(3-tert-butoxycarbonylamino-propionyloxy)-10,13-dimethyl-17-((R)-1-methyl-4-trityloxy-butyl)-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester
• Synonyms: 3-tert-Butoxycarbonylamino-propionic acid (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-bis-(3-tert-butoxycarbonylamino-propionyloxy)-10,13-dimethyl-17-((R)-1-methyl-4-trityloxy-butyl)-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester
• CAS NO: 222165-70-0
• Molecular Weight: 1150.5
• Mol File: 222165-70-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-tert-Butoxycarbonylamino-propionic acid (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-bis-(3-tert-butoxycarbonylamino-propionyloxy)-10,13-dimethyl-17-((R)-1-methyl-4-trityloxy-butyl)-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-tert-Butoxycarbonylamino-propionic acid (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-bis-(3-tert-butoxycarbonylamino-propionyloxy)-10,13-dimethyl-17-((R)-1-methyl-4-trityloxy-butyl)-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester(222165-70-0)
• EPA Substance Registry System: 3-tert-Butoxycarbonylamino-propionic acid (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7-bis-(3-tert-butoxycarbonylamino-propionyloxy)-10,13-dimethyl-17-((R)-1-methyl-4-trityloxy-butyl)-hexadecahydro-cyclopenta[a]phenanthren-12-yl ester(222165-70-0)

Safety Data

• Hazardous Substances Data: 222165-70-0(Hazardous Substances Data)

Upstream product

• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 203795-56-6 24-triphenylmethoxy-5β-cholan-3α,7α,12α-triol 

Relevant articles and documents

CATIONIC STEROID ANTIMICROBIAL DIAGNOSTIC, DETECTION, SCREENING AND IMAGING METHODS

The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA- 13 labeled with 99mTc is used to detect the presence of an infection.

Cationic Steroid Antimicrobial Compositions and Methods of Use

The invention provides methods for decreasing or inhibiting human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo, or an adverse side effect of human immunodeficiency virus (HIV) infection or pathogenesis (e.g., illness) in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

Steroid derived antibiotics

A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromycin and novobiocin.